Hematological malignancies
Conditions
Interventions
Index test:The sensitivity, specificity, accuracy, positive predictive value, and negative predictive value are calculated for CXCR4-targeted PET/CT imaging in the diagnosis and staging of hematologic
Sponsors
Zhongnan Hospital of Wuhan University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients who are voluntary to participate and sign an informed consent form; 2. Aged 18 - 90 years; 3. Newly diagnosed patients with highly suspected or confirmed hematological malignancies; 4. Patients had a history of hematological malignancy, complete remission after treatment, and recurrence; 5. Willing and able to follow scheduled visits, treatment plans, and laboratory tests.
Exclusion criteria
Exclusion criteria: 1. Pregnancy or breastfeeding; 2. Allergic to CXCR4-targeted tracers or excipients; 3. Fasting blood glucose level exceeded 11.0 mmol/L prior to injection of 18F-FDG; 4. Those who cannot complete PET/CT scan, including the inability to keep supine, claustrophobia, radiation phobia, etc.; 5. Researchers think it is inappropriate to participate in this clinical trial for patients with a poor compliance or other unsuitable factors.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| SUV;Size of lesion;Site of infiltration;Accuracy, Sensitivity, Specificity, Positive predictive value, Negative predictive value; | — |
Countries
China
Contacts
Public ContactYong He
Zhongnan Hospital of Wuhan University
Outcome results
None listed